Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Tarek M. Mekhail

Hematology Oncology | Hematology | Oncology
AdventHealth
Florida Hospital Medical Group Inc
2501 N Orange Ave, Suite 689, 
Orlando, FL 
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
AdventHealth
Florida Hospital Medical Group Inc
2501 N Orange Ave, Suite 689, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tarek Mekhail is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Mekhail is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Mekhail is currently accepting new patients.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Adventhealth Orlando
Adventhealth Waterman
Adventhealth Deland
Languages Spoken
English
Arabic
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

FLORIDA HOSPITAL MEDICAL GROUP INC
2501 N Orange Ave, Suite 689, Orlando, FL 32804
Call: 407-303-2024
Other Locations
FLORIDA HOSPITAL MEDICAL GROUP INC
601 E Rollins St, Orlando, FL 32803
Call: 407-303-2570
FLORIDA HOSPITAL MEDICAL GROUP INC
2600 Westhall Ln, Maitland, FL 32751
Call: 407-200-2700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: April 23, 2025
Intervention Type: Drug, Device
Study Phase: Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Enrollment Status: Terminated
Publish Date: August 15, 2024
Intervention Type: Drug
Study Drug: VLS-101
Study Phase: Phase 2
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

50 Total Publications

Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Journal: Clinical lung cancer
Published: August 28, 2024
View All 50 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Carlos A. Alemany
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Carlos A. Alemany
Hematology Oncology | Oncology

Florida Hospital Medical Group Inc

2600 Westhall Ln, 
Maitland, FL 
 (4.5 miles away)
407-200-2700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlos Alemany is a Hematologist Oncology specialist and an Oncologist in Maitland, Florida. Dr. Alemany is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and WT1-Related Wilms Tumor Syndromes. Dr. Alemany is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Guru P. Sonpavde
Oncology | Hematology Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Guru P. Sonpavde
Oncology | Hematology Oncology | Hematology

Florida Hospital Medical Group Inc

2501 N Orange Ave, Suite 689, 
Orlando, FL 
 (0.1 miles away)
407-303-2024
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Guru Sonpavde is an Oncologist and a Hematologist Oncology provider in Orlando, Florida. Dr. Sonpavde is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Boon Y. Chew
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Boon Y. Chew
Hematology Oncology | Oncology | Hematology

Halifax Healthcare Systems Inc

1041 Dunlawon Ave, 
Port Orange, FL 
 (44.0 miles away)
386-322-4700
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Boon Chew is a Hematologist Oncology specialist and an Oncologist in Port Orange, Florida. Dr. Chew is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Chew is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mekhail's expertise for a condition
ConditionClose
  • Elite
  • EGFR Positive Lung Cancer
    Dr. Mekhail is
    Elite
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Lung Cancer
    Dr. Mekhail is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Mekhail is
    Elite
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Distinguished
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Mekhail is
    Distinguished
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Familial Colorectal Cancer
    Dr. Mekhail is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Mekhail is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Glioma
    Dr. Mekhail is
    Distinguished
    . Learn about Glioma.
    See more Glioma experts
  • Large-Cell Lung Carcinoma
    Dr. Mekhail is
    Distinguished
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Lung Adenocarcinoma
    Dr. Mekhail is
    Distinguished
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
View All 20 Distinguished Conditions
  • Advanced
  • Acute Hepatic Porphyria (AHP)
    Dr. Mekhail is
    Advanced
    . Learn about Acute Hepatic Porphyria (AHP).
    See more Acute Hepatic Porphyria (AHP) experts
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Mekhail is
    Advanced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Mekhail is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Mekhail is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Mekhail is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adult Immune Thrombocytopenia
    Dr. Mekhail is
    Advanced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
View All 108 Advanced Conditions
  • Experienced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Mekhail is
    Experienced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Acute Intermittent Porphyria
    Dr. Mekhail is
    Experienced
    . Learn about Acute Intermittent Porphyria.
    See more Acute Intermittent Porphyria experts
  • Acute Mountain Sickness
    Dr. Mekhail is
    Experienced
    . Learn about Acute Mountain Sickness.
    See more Acute Mountain Sickness experts
  • Acute Myelomonocytic Leukemia
    Dr. Mekhail is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Acute Promyelocytic Leukemia
    Dr. Mekhail is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Adenoid Cystic Carcinoma
    Dr. Mekhail is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
View All 128 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved